1,199,300 Shares in Tetraphase Pharmaceuticals, Inc. (TTPH) Purchased by JPMorgan Chase & Co.
JPMorgan Chase & Co. bought a new position in shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 1,199,300 shares of the biopharmaceutical company’s stock, valued at approximately $7,915,000. JPMorgan Chase & Co. owned about 2.33% of Tetraphase Pharmaceuticals as of its most recent SEC filing.
A number of other large investors have also recently added to or reduced their stakes in TTPH. American International Group Inc. lifted its holdings in shares of Tetraphase Pharmaceuticals by 44.1% in the 3rd quarter. American International Group Inc. now owns 33,826 shares of the biopharmaceutical company’s stock worth $231,000 after purchasing an additional 10,345 shares during the last quarter. Brighton Jones LLC bought a new stake in Tetraphase Pharmaceuticals during the 3rd quarter valued at $108,000. SG Americas Securities LLC bought a new stake in Tetraphase Pharmaceuticals during the 3rd quarter valued at $107,000. Bank of New York Mellon Corp raised its stake in Tetraphase Pharmaceuticals by 21.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 235,309 shares of the biopharmaceutical company’s stock valued at $1,609,000 after acquiring an additional 41,165 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. raised its stake in Tetraphase Pharmaceuticals by 95.5% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 393,000 shares of the biopharmaceutical company’s stock valued at $2,688,000 after acquiring an additional 192,000 shares in the last quarter. 58.15% of the stock is currently owned by institutional investors.
Several analysts have weighed in on TTPH shares. HC Wainwright lifted their target price on Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, November 6th. Zacks Investment Research downgraded Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 4th. ValuEngine cut Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. BMO Capital Markets lifted their price target on Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an “outperform” rating in a research report on Wednesday, October 4th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $13.00 price target on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, September 12th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $15.15.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.63). The business had revenue of $4.10 million for the quarter, compared to analysts’ expectations of $1.59 million. Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The company’s quarterly revenue was up 355.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.58) EPS. research analysts forecast that Tetraphase Pharmaceuticals, Inc. will post -2.88 EPS for the current year.
In other Tetraphase Pharmaceuticals news, Director L Patrick Gage bought 3,880 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The stock was acquired at an average price of $6.45 per share, with a total value of $25,026.00. Following the completion of the transaction, the director now directly owns 38,880 shares in the company, valued at approximately $250,776. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Jacques Dumas sold 8,750 shares of the firm’s stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $6.03, for a total value of $52,762.50. Following the completion of the sale, the insider now directly owns 8,750 shares of the company’s stock, valued at approximately $52,762.50. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.
Tetraphase Pharmaceuticals Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.